Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited invites shareholders to a General Meeting on November 4, 2024, urging them to lodge proxy forms by November 2 and submit questions in advance for a more informative session. The company is transitioning to electronic communications for meeting documents and shareholder updates, with hard copies available only upon request. Actinogen is developing Xanamem, a novel therapy for Alzheimer’s, Depression, and potentially other neurological conditions, with promising clinical trial results indicating significant benefits in depression and potential in Alzheimer’s disease management.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
